
Procter & Gamble Health Limited (NSE: PGHL.NS) Stock Competitors & Peer Comparison
See PGHL.NS's competitors and their performance on the NSE and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for PGHL.NS and its NSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PGHL.NS | ₹5,589.50 | +0.96% | 92.8B | 26.01 | ₹214.92 | +4.47% |
| SUNPHARMA.NS | ₹1,884.90 | -0.79% | 4.5T | 36.61 | ₹51.48 | +0.85% |
| SUNPHARMA.BO | ₹1,885.10 | -0.94% | 4.5T | 36.96 | ₹51.00 | +0.85% |
| DIVISLAB.NS | ₹11,180.50 | +0.02% | 3T | 101.50 | ₹110.15 | +0.27% |
| DIVISLAB.BO | ₹11,200.00 | +0.20% | 3T | 101.64 | ₹110.19 | +0.27% |
| TORNTPHARM.NS | ₹4,689.50 | +1.70% | 1.8T | 76.43 | ₹61.36 | +0.81% |
| TORNTPHARM.BO | ₹4,698.80 | +1.79% | 1.8T | 76.47 | ₹61.45 | +0.81% |
| LAURUSLABS.NS | ₹2,294.60 | -0.49% | 1.2T | 92.26 | ₹24.87 | +0.10% |
| LAURUSLABS.BO | ₹2,295.00 | -0.30% | 1.2T | 92.17 | ₹24.90 | +0.10% |
| ZYDUSLIFE.NS | ₹1,200.00 | -0.24% | 1.2T | 28.10 | ₹42.71 | +0.08% |
Stock Comparison
Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA.NS)
PGHL.NS vs SUNPHARMA.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, SUNPHARMA.NS has a market cap of 4.5T. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while SUNPHARMA.NS trades at ₹1,884.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas SUNPHARMA.NS's P/E ratio is 36.61. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to SUNPHARMA.NS's ROE of +0.13%. Regarding short-term risk, PGHL.NS is more volatile compared to SUNPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check SUNPHARMA.NS's competition here
Sun Pharmaceutical Industries Limited (BSE: SUNPHARMA.BO)
PGHL.NS vs SUNPHARMA.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, SUNPHARMA.BO has a market cap of 4.5T. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while SUNPHARMA.BO trades at ₹1,885.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas SUNPHARMA.BO's P/E ratio is 36.96. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to SUNPHARMA.BO's ROE of +0.13%. Regarding short-term risk, PGHL.NS is more volatile compared to SUNPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check SUNPHARMA.BO's competition here
Divi's Laboratories Limited (NSE: DIVISLAB.NS)
PGHL.NS vs DIVISLAB.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, DIVISLAB.NS has a market cap of 3T. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while DIVISLAB.NS trades at ₹11,180.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas DIVISLAB.NS's P/E ratio is 101.50. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to DIVISLAB.NS's ROE of +0.20%. Regarding short-term risk, PGHL.NS is more volatile compared to DIVISLAB.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check DIVISLAB.NS's competition here
Divi's Laboratories Limited (BSE: DIVISLAB.BO)
PGHL.NS vs DIVISLAB.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, DIVISLAB.BO has a market cap of 3T. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while DIVISLAB.BO trades at ₹11,200.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas DIVISLAB.BO's P/E ratio is 101.64. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to DIVISLAB.BO's ROE of +0.20%. Regarding short-term risk, PGHL.NS is more volatile compared to DIVISLAB.BO. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check DIVISLAB.BO's competition here
Torrent Pharmaceuticals Limited (NSE: TORNTPHARM.NS)
PGHL.NS vs TORNTPHARM.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, TORNTPHARM.NS has a market cap of 1.8T. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while TORNTPHARM.NS trades at ₹4,689.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas TORNTPHARM.NS's P/E ratio is 76.43. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to TORNTPHARM.NS's ROE of +0.16%. Regarding short-term risk, PGHL.NS is more volatile compared to TORNTPHARM.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check TORNTPHARM.NS's competition here
Torrent Pharmaceuticals Limited (BSE: TORNTPHARM.BO)
PGHL.NS vs TORNTPHARM.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, TORNTPHARM.BO has a market cap of 1.8T. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while TORNTPHARM.BO trades at ₹4,698.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas TORNTPHARM.BO's P/E ratio is 76.47. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to TORNTPHARM.BO's ROE of +0.16%. Regarding short-term risk, PGHL.NS is more volatile compared to TORNTPHARM.BO. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check TORNTPHARM.BO's competition here
Laurus Labs Limited (NSE: LAURUSLABS.NS)
PGHL.NS vs LAURUSLABS.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, LAURUSLABS.NS has a market cap of 1.2T. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while LAURUSLABS.NS trades at ₹2,294.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas LAURUSLABS.NS's P/E ratio is 92.26. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to LAURUSLABS.NS's ROE of +0.25%. Regarding short-term risk, PGHL.NS is more volatile compared to LAURUSLABS.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check LAURUSLABS.NS's competition here
Laurus Labs Limited (BSE: LAURUSLABS.BO)
PGHL.NS vs LAURUSLABS.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, LAURUSLABS.BO has a market cap of 1.2T. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while LAURUSLABS.BO trades at ₹2,295.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas LAURUSLABS.BO's P/E ratio is 92.17. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to LAURUSLABS.BO's ROE of +0.25%. Regarding short-term risk, PGHL.NS is more volatile compared to LAURUSLABS.BO. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check LAURUSLABS.BO's competition here
Zydus Lifesciences Limited (NSE: ZYDUSLIFE.NS)
PGHL.NS vs ZYDUSLIFE.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, ZYDUSLIFE.NS has a market cap of 1.2T. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while ZYDUSLIFE.NS trades at ₹1,200.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas ZYDUSLIFE.NS's P/E ratio is 28.10. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to ZYDUSLIFE.NS's ROE of +0.15%. Regarding short-term risk, PGHL.NS is more volatile compared to ZYDUSLIFE.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check ZYDUSLIFE.NS's competition here
Zydus Lifesciences Limited (BSE: ZYDUSLIFE.BO)
PGHL.NS vs ZYDUSLIFE.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, ZYDUSLIFE.BO has a market cap of 1.2T. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while ZYDUSLIFE.BO trades at ₹1,195.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas ZYDUSLIFE.BO's P/E ratio is 28.15. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to ZYDUSLIFE.BO's ROE of +0.15%. Regarding short-term risk, PGHL.NS is more volatile compared to ZYDUSLIFE.BO. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check ZYDUSLIFE.BO's competition here
Dr. Reddy's Laboratories Limited (NSE: DRREDDY.NS)
PGHL.NS vs DRREDDY.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, DRREDDY.NS has a market cap of 1.2T. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while DRREDDY.NS trades at ₹1,390.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas DRREDDY.NS's P/E ratio is 41.39. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to DRREDDY.NS's ROE of +0.07%. Regarding short-term risk, PGHL.NS is more volatile compared to DRREDDY.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check DRREDDY.NS's competition here
Dr. Reddy's Laboratories Limited (BSE: DRREDDY.BO)
PGHL.NS vs DRREDDY.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, DRREDDY.BO has a market cap of 1.2T. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while DRREDDY.BO trades at ₹1,390.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas DRREDDY.BO's P/E ratio is 41.40. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to DRREDDY.BO's ROE of +0.07%. Regarding short-term risk, PGHL.NS is more volatile compared to DRREDDY.BO. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check DRREDDY.BO's competition here
Cipla Limited (NSE: CIPLA.NS)
PGHL.NS vs CIPLA.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, CIPLA.NS has a market cap of 1.1T. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while CIPLA.NS trades at ₹1,415.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas CIPLA.NS's P/E ratio is 39.48. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to CIPLA.NS's ROE of +0.08%. Regarding short-term risk, PGHL.NS is more volatile compared to CIPLA.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check CIPLA.NS's competition here
Cipla Limited (BSE: CIPLA.BO)
PGHL.NS vs CIPLA.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, CIPLA.BO has a market cap of 1.1T. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while CIPLA.BO trades at ₹1,414.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas CIPLA.BO's P/E ratio is 39.49. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to CIPLA.BO's ROE of +0.08%. Regarding short-term risk, PGHL.NS is more volatile compared to CIPLA.BO. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check CIPLA.BO's competition here
Mankind Pharma Limited (NSE: MANKIND.NS)
PGHL.NS vs MANKIND.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, MANKIND.NS has a market cap of 1.1T. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while MANKIND.NS trades at ₹2,665.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas MANKIND.NS's P/E ratio is 50.99. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to MANKIND.NS's ROE of +0.14%. Regarding short-term risk, PGHL.NS is more volatile compared to MANKIND.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check MANKIND.NS's competition here
Mankind Pharma Limited (BSE: MANKIND.BO)
PGHL.NS vs MANKIND.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, MANKIND.BO has a market cap of 1.1T. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while MANKIND.BO trades at ₹2,660.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas MANKIND.BO's P/E ratio is 50.88. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to MANKIND.BO's ROE of +0.14%. Regarding short-term risk, PGHL.NS is more volatile compared to MANKIND.BO. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check MANKIND.BO's competition here
Aurobindo Pharma Limited (NSE: AUROPHARMA.NS)
PGHL.NS vs AUROPHARMA.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, AUROPHARMA.NS has a market cap of 1T. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while AUROPHARMA.NS trades at ₹1,799.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas AUROPHARMA.NS's P/E ratio is 28.11. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to AUROPHARMA.NS's ROE of +0.11%. Regarding short-term risk, PGHL.NS is more volatile compared to AUROPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check AUROPHARMA.NS's competition here
Aurobindo Pharma Limited (BSE: AUROPHARMA.BO)
PGHL.NS vs AUROPHARMA.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, AUROPHARMA.BO has a market cap of 1T. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while AUROPHARMA.BO trades at ₹1,795.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas AUROPHARMA.BO's P/E ratio is 28.05. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to AUROPHARMA.BO's ROE of +0.11%. Regarding short-term risk, PGHL.NS is more volatile compared to AUROPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check AUROPHARMA.BO's competition here
Lupin Limited (NSE: LUPIN.NS)
PGHL.NS vs LUPIN.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, LUPIN.NS has a market cap of 921B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while LUPIN.NS trades at ₹2,014.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas LUPIN.NS's P/E ratio is 15.81. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to LUPIN.NS's ROE of +0.23%. Regarding short-term risk, PGHL.NS is more volatile compared to LUPIN.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check LUPIN.NS's competition here
Lupin Limited (BSE: LUPIN.BO)
PGHL.NS vs LUPIN.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, LUPIN.BO has a market cap of 921B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while LUPIN.BO trades at ₹2,010.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas LUPIN.BO's P/E ratio is 15.78. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to LUPIN.BO's ROE of +0.23%. Regarding short-term risk, PGHL.NS is more volatile compared to LUPIN.BO. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check LUPIN.BO's competition here
Glenmark Pharmaceuticals Limited (BSE: GLENMARK.BO)
PGHL.NS vs GLENMARK.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, GLENMARK.BO has a market cap of 747.3B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while GLENMARK.BO trades at ₹2,648.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas GLENMARK.BO's P/E ratio is 41.58. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to GLENMARK.BO's ROE of +0.14%. Regarding short-term risk, PGHL.NS is more volatile compared to GLENMARK.BO. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check GLENMARK.BO's competition here
Glenmark Pharmaceuticals Limited (NSE: GLENMARK.NS)
PGHL.NS vs GLENMARK.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, GLENMARK.NS has a market cap of 747.3B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while GLENMARK.NS trades at ₹2,648.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas GLENMARK.NS's P/E ratio is 43.40. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to GLENMARK.NS's ROE of +0.14%. Regarding short-term risk, PGHL.NS is more volatile compared to GLENMARK.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check GLENMARK.NS's competition here
Alkem Laboratories Limited (NSE: ALKEM.NS)
PGHL.NS vs ALKEM.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, ALKEM.NS has a market cap of 619.9B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while ALKEM.NS trades at ₹5,185.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas ALKEM.NS's P/E ratio is 28.70. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to ALKEM.NS's ROE of +0.15%. Regarding short-term risk, PGHL.NS is more volatile compared to ALKEM.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check ALKEM.NS's competition here
Alkem Laboratories Limited (BSE: ALKEM.BO)
PGHL.NS vs ALKEM.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, ALKEM.BO has a market cap of 619.9B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while ALKEM.BO trades at ₹5,168.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas ALKEM.BO's P/E ratio is 28.64. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to ALKEM.BO's ROE of +0.15%. Regarding short-term risk, PGHL.NS is more volatile compared to ALKEM.BO. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check ALKEM.BO's competition here
Gland Pharma Limited (NSE: GLAND.NS)
PGHL.NS vs GLAND.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, GLAND.NS has a market cap of 549.8B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while GLAND.NS trades at ₹3,331.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas GLAND.NS's P/E ratio is 48.59. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to GLAND.NS's ROE of +0.12%. Regarding short-term risk, PGHL.NS is more volatile compared to GLAND.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check GLAND.NS's competition here
Gland Pharma Limited (BSE: GLAND.BO)
PGHL.NS vs GLAND.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, GLAND.BO has a market cap of 549.8B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while GLAND.BO trades at ₹3,331.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas GLAND.BO's P/E ratio is 48.60. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to GLAND.BO's ROE of +0.12%. Regarding short-term risk, PGHL.NS is more volatile compared to GLAND.BO. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check GLAND.BO's competition here
Ipca Laboratories Limited (NSE: IPCALAB.NS)
PGHL.NS vs IPCALAB.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, IPCALAB.NS has a market cap of 467.8B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while IPCALAB.NS trades at ₹1,843.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas IPCALAB.NS's P/E ratio is 34.63. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to IPCALAB.NS's ROE of +0.17%. Regarding short-term risk, PGHL.NS is more volatile compared to IPCALAB.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check IPCALAB.NS's competition here
Ipca Laboratories Limited (BSE: IPCALAB.BO)
PGHL.NS vs IPCALAB.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, IPCALAB.BO has a market cap of 467.8B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while IPCALAB.BO trades at ₹1,845.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas IPCALAB.BO's P/E ratio is 34.85. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to IPCALAB.BO's ROE of +0.17%. Regarding short-term risk, PGHL.NS is more volatile compared to IPCALAB.BO. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check IPCALAB.BO's competition here
Emcure Pharmaceuticals Ltd. (NSE: EMCURE.NS)
PGHL.NS vs EMCURE.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, EMCURE.NS has a market cap of 443.5B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while EMCURE.NS trades at ₹2,337.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas EMCURE.NS's P/E ratio is 42.74. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to EMCURE.NS's ROE of +0.22%. Regarding short-term risk, PGHL.NS is more volatile compared to EMCURE.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check EMCURE.NS's competition here
Ajanta Pharma Limited (NSE: AJANTPHARM.NS)
PGHL.NS vs AJANTPHARM.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, AJANTPHARM.NS has a market cap of 414.6B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while AJANTPHARM.NS trades at ₹3,317.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas AJANTPHARM.NS's P/E ratio is 32.86. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to AJANTPHARM.NS's ROE of +0.28%. Regarding short-term risk, PGHL.NS is more volatile compared to AJANTPHARM.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check AJANTPHARM.NS's competition here
Ajanta Pharma Limited (BSE: AJANTPHARM.BO)
PGHL.NS vs AJANTPHARM.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, AJANTPHARM.BO has a market cap of 414.6B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while AJANTPHARM.BO trades at ₹3,316.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas AJANTPHARM.BO's P/E ratio is 32.85. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to AJANTPHARM.BO's ROE of +0.28%. Regarding short-term risk, PGHL.NS is more volatile compared to AJANTPHARM.BO. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check AJANTPHARM.BO's competition here
Suven Pharmaceuticals Limited (NSE: SUVENPHAR.NS)
PGHL.NS vs SUVENPHAR.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, SUVENPHAR.NS has a market cap of 412.4B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while SUVENPHAR.NS trades at ₹1,078.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas SUVENPHAR.NS's P/E ratio is 98.90. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to SUVENPHAR.NS's ROE of +0.03%. Regarding short-term risk, PGHL.NS is more volatile compared to SUVENPHAR.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check SUVENPHAR.NS's competition here
Suven Pharmaceuticals Limited (BSE: SUVENPHAR.BO)
PGHL.NS vs SUVENPHAR.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, SUVENPHAR.BO has a market cap of 411.4B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while SUVENPHAR.BO trades at ₹1,075.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas SUVENPHAR.BO's P/E ratio is 98.29. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to SUVENPHAR.BO's ROE of +0.16%. Regarding short-term risk, PGHL.NS is more volatile compared to SUVENPHAR.BO. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check SUVENPHAR.BO's competition here
Piramal Pharma Limited (NSE: PPLPHARMA.NS)
PGHL.NS vs PPLPHARMA.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, PPLPHARMA.NS has a market cap of 317.3B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while PPLPHARMA.NS trades at ₹239.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas PPLPHARMA.NS's P/E ratio is -204.33. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to PPLPHARMA.NS's ROE of -0.03%. Regarding short-term risk, PGHL.NS is more volatile compared to PPLPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check PPLPHARMA.NS's competition here
Piramal Pharma Limited (BSE: PPLPHARMA.BO)
PGHL.NS vs PPLPHARMA.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, PPLPHARMA.BO has a market cap of 316.7B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while PPLPHARMA.BO trades at ₹239.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas PPLPHARMA.BO's P/E ratio is -203.69. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to PPLPHARMA.BO's ROE of -0.03%. Regarding short-term risk, PGHL.NS is more volatile compared to PPLPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check PPLPHARMA.BO's competition here
Neuland Laboratories Limited (NSE: NEULANDLAB.NS)
PGHL.NS vs NEULANDLAB.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, NEULANDLAB.NS has a market cap of 264.8B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while NEULANDLAB.NS trades at ₹20,642.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas NEULANDLAB.NS's P/E ratio is 52.33. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to NEULANDLAB.NS's ROE of +0.24%. Regarding short-term risk, PGHL.NS is more volatile compared to NEULANDLAB.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check NEULANDLAB.NS's competition here
Neuland Laboratories Limited (BSE: NEULANDLAB.BO)
PGHL.NS vs NEULANDLAB.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, NEULANDLAB.BO has a market cap of 264.8B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while NEULANDLAB.BO trades at ₹20,633.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas NEULANDLAB.BO's P/E ratio is 52.46. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to NEULANDLAB.BO's ROE of +0.24%. Regarding short-term risk, PGHL.NS is more volatile compared to NEULANDLAB.BO. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check NEULANDLAB.BO's competition here
Piramal Enterprises Limited (NSE: PEL.NS)
PGHL.NS vs PEL.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while PEL.NS trades at ₹1,124.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to PEL.NS's ROE of +0.02%. Regarding short-term risk, PGHL.NS is less volatile compared to PEL.NS. This indicates lower risk in terms of short-term price fluctuations for PGHL.NS.Check PEL.NS's competition here
Alembic Pharmaceuticals Limited (NSE: APLLTD.NS)
PGHL.NS vs APLLTD.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, APLLTD.NS has a market cap of 204.6B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while APLLTD.NS trades at ₹1,040.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas APLLTD.NS's P/E ratio is 27.25. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to APLLTD.NS's ROE of +0.15%. Regarding short-term risk, PGHL.NS is more volatile compared to APLLTD.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check APLLTD.NS's competition here
Alembic Pharmaceuticals Limited (BSE: APLLTD.BO)
PGHL.NS vs APLLTD.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, APLLTD.BO has a market cap of 204.6B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while APLLTD.BO trades at ₹1,041.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas APLLTD.BO's P/E ratio is 27.26. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to APLLTD.BO's ROE of +0.15%. Regarding short-term risk, PGHL.NS is more volatile compared to APLLTD.BO. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check APLLTD.BO's competition here
Granules India Limited (NSE: GRANULES.NS)
PGHL.NS vs GRANULES.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, GRANULES.NS has a market cap of 203.9B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while GRANULES.NS trades at ₹822.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas GRANULES.NS's P/E ratio is 31.26. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to GRANULES.NS's ROE of +0.14%. Regarding short-term risk, PGHL.NS is less volatile compared to GRANULES.NS. This indicates lower risk in terms of short-term price fluctuations for PGHL.NS.Check GRANULES.NS's competition here
Granules India Limited (BSE: GRANULES.BO)
PGHL.NS vs GRANULES.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, GRANULES.BO has a market cap of 203.9B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while GRANULES.BO trades at ₹823.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas GRANULES.BO's P/E ratio is 31.50. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to GRANULES.BO's ROE of +0.14%. Regarding short-term risk, PGHL.NS is less volatile compared to GRANULES.BO. This indicates lower risk in terms of short-term price fluctuations for PGHL.NS.Check GRANULES.BO's competition here
Eris Lifesciences Limited (NSE: ERIS.NS)
PGHL.NS vs ERIS.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, ERIS.NS has a market cap of 182.7B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while ERIS.NS trades at ₹1,317.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas ERIS.NS's P/E ratio is 37.26. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to ERIS.NS's ROE of +0.19%. Regarding short-term risk, PGHL.NS is more volatile compared to ERIS.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check ERIS.NS's competition here
Eris Lifesciences Limited (BSE: ERIS.BO)
PGHL.NS vs ERIS.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, ERIS.BO has a market cap of 182.7B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while ERIS.BO trades at ₹1,319.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas ERIS.BO's P/E ratio is 42.79. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to ERIS.BO's ROE of +0.19%. Regarding short-term risk, PGHL.NS is more volatile compared to ERIS.BO. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check ERIS.BO's competition here
Cohance Lifesciences Limited (NSE: COHANCE.NS)
PGHL.NS vs COHANCE.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, COHANCE.NS has a market cap of 176.9B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while COHANCE.NS trades at ₹462.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas COHANCE.NS's P/E ratio is 139.81. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to COHANCE.NS's ROE of +0.01%. Regarding short-term risk, PGHL.NS is more volatile compared to COHANCE.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check COHANCE.NS's competition here
Cohance Lifesciences Limited (BSE: COHANCE.BO)
PGHL.NS vs COHANCE.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, COHANCE.BO has a market cap of 176.9B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while COHANCE.BO trades at ₹462.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas COHANCE.BO's P/E ratio is 145.97. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to COHANCE.BO's ROE of +0.01%. Regarding short-term risk, PGHL.NS is more volatile compared to COHANCE.BO. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check COHANCE.BO's competition here
Alivus Life Sciences Limited (NSE: ALIVUS.NS)
PGHL.NS vs ALIVUS.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, ALIVUS.NS has a market cap of 176.7B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while ALIVUS.NS trades at ₹1,436.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas ALIVUS.NS's P/E ratio is 25.25. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to ALIVUS.NS's ROE of +0.20%. Regarding short-term risk, PGHL.NS is more volatile compared to ALIVUS.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check ALIVUS.NS's competition here
Alivus Life Sciences Limited (BSE: ALIVUS.BO)
PGHL.NS vs ALIVUS.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, ALIVUS.BO has a market cap of 176.4B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while ALIVUS.BO trades at ₹1,434.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas ALIVUS.BO's P/E ratio is 26.28. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to ALIVUS.BO's ROE of +0.20%. Regarding short-term risk, PGHL.NS is more volatile compared to ALIVUS.BO. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check ALIVUS.BO's competition here
Shilpa Medicare Limited (NSE: SHILPAMED.NS)
PGHL.NS vs SHILPAMED.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, SHILPAMED.NS has a market cap of 166.1B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while SHILPAMED.NS trades at ₹849.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas SHILPAMED.NS's P/E ratio is 53.95. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to SHILPAMED.NS's ROE of +0.13%. Regarding short-term risk, PGHL.NS is less volatile compared to SHILPAMED.NS. This indicates lower risk in terms of short-term price fluctuations for PGHL.NS.Check SHILPAMED.NS's competition here
NATCO Pharma Limited (NSE: NATCOPHARM.NS)
PGHL.NS vs NATCOPHARM.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, NATCOPHARM.NS has a market cap of 159.7B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while NATCOPHARM.NS trades at ₹814.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas NATCOPHARM.NS's P/E ratio is 13.43. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to NATCOPHARM.NS's ROE of +0.09%. Regarding short-term risk, PGHL.NS is more volatile compared to NATCOPHARM.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check NATCOPHARM.NS's competition here
NATCO Pharma Limited (BSE: NATCOPHARM.BO)
PGHL.NS vs NATCOPHARM.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, NATCOPHARM.BO has a market cap of 159.7B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while NATCOPHARM.BO trades at ₹817.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas NATCOPHARM.BO's P/E ratio is 13.48. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to NATCOPHARM.BO's ROE of +0.09%. Regarding short-term risk, PGHL.NS is more volatile compared to NATCOPHARM.BO. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check NATCOPHARM.BO's competition here
Caplin Point Laboratories Limited (NSE: CAPLIPOINT.NS)
PGHL.NS vs CAPLIPOINT.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, CAPLIPOINT.NS has a market cap of 154.2B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while CAPLIPOINT.NS trades at ₹2,029.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas CAPLIPOINT.NS's P/E ratio is 23.84. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to CAPLIPOINT.NS's ROE of +0.20%. Regarding short-term risk, PGHL.NS is less volatile compared to CAPLIPOINT.NS. This indicates lower risk in terms of short-term price fluctuations for PGHL.NS.Check CAPLIPOINT.NS's competition here
Caplin Point Laboratories Limited (BSE: CAPLIPOINT.BO)
PGHL.NS vs CAPLIPOINT.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, CAPLIPOINT.BO has a market cap of 154.2B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while CAPLIPOINT.BO trades at ₹2,028.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas CAPLIPOINT.BO's P/E ratio is 23.84. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to CAPLIPOINT.BO's ROE of +0.20%. Regarding short-term risk, PGHL.NS is less volatile compared to CAPLIPOINT.BO. This indicates lower risk in terms of short-term price fluctuations for PGHL.NS.Check CAPLIPOINT.BO's competition here
AstraZeneca Pharma India Limited (NSE: ASTRAZEN.NS)
PGHL.NS vs ASTRAZEN.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, ASTRAZEN.NS has a market cap of 154.2B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while ASTRAZEN.NS trades at ₹6,167.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas ASTRAZEN.NS's P/E ratio is 90.90. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to ASTRAZEN.NS's ROE of +0.21%. Regarding short-term risk, PGHL.NS is more volatile compared to ASTRAZEN.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check ASTRAZEN.NS's competition here
AstraZeneca Pharma India Limited (BSE: ASTRAZEN.BO)
PGHL.NS vs ASTRAZEN.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, ASTRAZEN.BO has a market cap of 154.2B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while ASTRAZEN.BO trades at ₹6,158.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas ASTRAZEN.BO's P/E ratio is 90.77. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to ASTRAZEN.BO's ROE of +0.21%. Regarding short-term risk, PGHL.NS is more volatile compared to ASTRAZEN.BO. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check ASTRAZEN.BO's competition here
Jubilant Pharmova Limited (NSE: JUBLPHARMA.NS)
PGHL.NS vs JUBLPHARMA.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, JUBLPHARMA.NS has a market cap of 148.1B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while JUBLPHARMA.NS trades at ₹935.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas JUBLPHARMA.NS's P/E ratio is 38.75. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to JUBLPHARMA.NS's ROE of +0.04%. Regarding short-term risk, PGHL.NS is more volatile compared to JUBLPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check JUBLPHARMA.NS's competition here
Jubilant Pharmova Limited (BSE: JUBLPHARMA.BO)
PGHL.NS vs JUBLPHARMA.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, JUBLPHARMA.BO has a market cap of 148.1B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while JUBLPHARMA.BO trades at ₹934.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas JUBLPHARMA.BO's P/E ratio is 38.76. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to JUBLPHARMA.BO's ROE of +0.04%. Regarding short-term risk, PGHL.NS is more volatile compared to JUBLPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check JUBLPHARMA.BO's competition here
Sudeep Pharma Ltd. (NSE: SUDEEPPHRM.NS)
PGHL.NS vs SUDEEPPHRM.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, SUDEEPPHRM.NS has a market cap of 134.6B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while SUDEEPPHRM.NS trades at ₹1,191.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas SUDEEPPHRM.NS's P/E ratio is 73.69. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to SUDEEPPHRM.NS's ROE of N/A. Regarding short-term risk, PGHL.NS is more volatile compared to SUDEEPPHRM.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check SUDEEPPHRM.NS's competition here
Glenmark Life Sciences Limited (NSE: GLS.NS)
PGHL.NS vs GLS.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while GLS.NS trades at ₹1,086.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to GLS.NS's ROE of +0.21%. Regarding short-term risk, PGHL.NS is more volatile compared to GLS.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check GLS.NS's competition here
Glenmark Life Sciences Limited (BSE: GLS.BO)
PGHL.NS vs GLS.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while GLS.BO trades at ₹1,085.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to GLS.BO's ROE of +0.19%. Regarding short-term risk, PGHL.NS is more volatile compared to GLS.BO. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check GLS.BO's competition here
Caplin Point Laboratories Limited (BSE: CAPPL.BO)
PGHL.NS vs CAPPL.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while CAPPL.BO trades at ₹1,446.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to CAPPL.BO's ROE of +0.05%. Regarding short-term risk, PGHL.NS is less volatile compared to CAPPL.BO. This indicates lower risk in terms of short-term price fluctuations for PGHL.NS.Check CAPPL.BO's competition here
Akums Drugs & Pharmaceuticals Ltd. (NSE: AKUMS.NS)
PGHL.NS vs AKUMS.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, AKUMS.NS has a market cap of 106.6B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while AKUMS.NS trades at ₹696.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas AKUMS.NS's P/E ratio is 36.86. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to AKUMS.NS's ROE of +0.11%. Regarding short-term risk, PGHL.NS is more volatile compared to AKUMS.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check AKUMS.NS's competition here
Viyash Scientific Limited (NSE: VIYASH.NS)
PGHL.NS vs VIYASH.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, VIYASH.NS has a market cap of 103B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while VIYASH.NS trades at ₹233.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas VIYASH.NS's P/E ratio is 56.10. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to VIYASH.NS's ROE of +0.09%. Regarding short-term risk, PGHL.NS is more volatile compared to VIYASH.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check VIYASH.NS's competition here
Procter & Gamble Health Limited (BSE: PGHL.BO)
PGHL.NS vs PGHL.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, PGHL.BO has a market cap of 92.8B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while PGHL.BO trades at ₹5,602.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas PGHL.BO's P/E ratio is 26.07. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to PGHL.BO's ROE of +0.65%. Regarding short-term risk, PGHL.NS is more volatile compared to PGHL.BO. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check PGHL.BO's competition here
Aarti Pharmalabs Limited (NSE: AARTIPHARM.NS)
PGHL.NS vs AARTIPHARM.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, AARTIPHARM.NS has a market cap of 89.8B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while AARTIPHARM.NS trades at ₹990.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas AARTIPHARM.NS's P/E ratio is 42.14. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to AARTIPHARM.NS's ROE of +0.12%. Regarding short-term risk, PGHL.NS is more volatile compared to AARTIPHARM.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check AARTIPHARM.NS's competition here
Aarti Pharmalabs Limited (BSE: AARTIPHARM.BO)
PGHL.NS vs AARTIPHARM.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, AARTIPHARM.BO has a market cap of 89.8B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while AARTIPHARM.BO trades at ₹989.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas AARTIPHARM.BO's P/E ratio is 34.96. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to AARTIPHARM.BO's ROE of +0.12%. Regarding short-term risk, PGHL.NS is more volatile compared to AARTIPHARM.BO. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check AARTIPHARM.BO's competition here
Strides Pharma Science Limited (NSE: STAR.NS)
PGHL.NS vs STAR.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, STAR.NS has a market cap of 89.2B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while STAR.NS trades at ₹967.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas STAR.NS's P/E ratio is 14.55. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to STAR.NS's ROE of +0.20%. Regarding short-term risk, PGHL.NS is more volatile compared to STAR.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check STAR.NS's competition here
Strides Pharma Science Limited (BSE: STAR.BO)
PGHL.NS vs STAR.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, STAR.BO has a market cap of 89.2B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while STAR.BO trades at ₹964.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas STAR.BO's P/E ratio is 14.51. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to STAR.BO's ROE of +0.20%. Regarding short-term risk, PGHL.NS is more volatile compared to STAR.BO. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check STAR.BO's competition here
Shilpa Medicare Limited (BSE: SHILPAMED.BO)
PGHL.NS vs SHILPAMED.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, SHILPAMED.BO has a market cap of 83.2B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while SHILPAMED.BO trades at ₹850.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas SHILPAMED.BO's P/E ratio is 55.81. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to SHILPAMED.BO's ROE of +0.13%. Regarding short-term risk, PGHL.NS is less volatile compared to SHILPAMED.BO. This indicates lower risk in terms of short-term price fluctuations for PGHL.NS.Check SHILPAMED.BO's competition here
Bliss GVS Pharma Limited (NSE: BLISSGVS.NS)
PGHL.NS vs BLISSGVS.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, BLISSGVS.NS has a market cap of 68.1B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while BLISSGVS.NS trades at ₹640.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas BLISSGVS.NS's P/E ratio is 49.76. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to BLISSGVS.NS's ROE of +0.13%. Regarding short-term risk, PGHL.NS is less volatile compared to BLISSGVS.NS. This indicates lower risk in terms of short-term price fluctuations for PGHL.NS.Check BLISSGVS.NS's competition here
Bliss GVS Pharma Limited (BSE: BLISSGVS.BO)
PGHL.NS vs BLISSGVS.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, BLISSGVS.BO has a market cap of 68.1B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while BLISSGVS.BO trades at ₹643.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas BLISSGVS.BO's P/E ratio is 49.96. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to BLISSGVS.BO's ROE of +0.13%. Regarding short-term risk, PGHL.NS is less volatile compared to BLISSGVS.BO. This indicates lower risk in terms of short-term price fluctuations for PGHL.NS.Check BLISSGVS.BO's competition here
Sun Pharma Advanced Research Company Limited (NSE: SPARC.NS)
PGHL.NS vs SPARC.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, SPARC.NS has a market cap of 61.7B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while SPARC.NS trades at ₹190.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas SPARC.NS's P/E ratio is 3.97. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to SPARC.NS's ROE of +1.73%. Regarding short-term risk, PGHL.NS is more volatile compared to SPARC.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check SPARC.NS's competition here
Sun Pharma Advanced Research Company Limited (BSE: SPARC.BO)
PGHL.NS vs SPARC.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, SPARC.BO has a market cap of 61.7B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while SPARC.BO trades at ₹190.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas SPARC.BO's P/E ratio is 3.97. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to SPARC.BO's ROE of +1.73%. Regarding short-term risk, PGHL.NS is more volatile compared to SPARC.BO. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check SPARC.BO's competition here
FDC Limited (NSE: FDC.NS)
PGHL.NS vs FDC.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, FDC.NS has a market cap of 61.5B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while FDC.NS trades at ₹377.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas FDC.NS's P/E ratio is 19.62. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to FDC.NS's ROE of +0.12%. Regarding short-term risk, PGHL.NS is more volatile compared to FDC.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check FDC.NS's competition here
Suven Life Sciences Limited (NSE: SUVEN.NS)
PGHL.NS vs SUVEN.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, SUVEN.NS has a market cap of 61.4B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while SUVEN.NS trades at ₹269.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas SUVEN.NS's P/E ratio is -18.96. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to SUVEN.NS's ROE of -0.73%. Regarding short-term risk, PGHL.NS is less volatile compared to SUVEN.NS. This indicates lower risk in terms of short-term price fluctuations for PGHL.NS.Check SUVEN.NS's competition here
FDC Limited (BSE: FDC.BO)
PGHL.NS vs FDC.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, FDC.BO has a market cap of 61.4B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while FDC.BO trades at ₹377.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas FDC.BO's P/E ratio is 19.63. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to FDC.BO's ROE of +0.12%. Regarding short-term risk, PGHL.NS is more volatile compared to FDC.BO. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check FDC.BO's competition here
Suven Life Sciences Limited (BSE: SUVEN.BO)
PGHL.NS vs SUVEN.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, SUVEN.BO has a market cap of 61.3B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while SUVEN.BO trades at ₹269.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas SUVEN.BO's P/E ratio is -21.70. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to SUVEN.BO's ROE of -0.73%. Regarding short-term risk, PGHL.NS is less volatile compared to SUVEN.BO. This indicates lower risk in terms of short-term price fluctuations for PGHL.NS.Check SUVEN.BO's competition here
Innova Captab Limited (NSE: INNOVACAP.NS)
PGHL.NS vs INNOVACAP.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, INNOVACAP.NS has a market cap of 56B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while INNOVACAP.NS trades at ₹977.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas INNOVACAP.NS's P/E ratio is 45.97. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to INNOVACAP.NS's ROE of +0.15%. Regarding short-term risk, PGHL.NS is more volatile compared to INNOVACAP.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check INNOVACAP.NS's competition here
IOL Chemicals and Pharmaceuticals Limited (NSE: IOLCP.NS)
PGHL.NS vs IOLCP.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, IOLCP.NS has a market cap of 54B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while IOLCP.NS trades at ₹184.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas IOLCP.NS's P/E ratio is 30.08. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to IOLCP.NS's ROE of +0.11%. Regarding short-term risk, PGHL.NS is less volatile compared to IOLCP.NS. This indicates lower risk in terms of short-term price fluctuations for PGHL.NS.Check IOLCP.NS's competition here
IOL Chemicals and Pharmaceuticals Limited (BSE: IOLCP.BO)
PGHL.NS vs IOLCP.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, IOLCP.BO has a market cap of 54B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while IOLCP.BO trades at ₹184.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas IOLCP.BO's P/E ratio is 30.18. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to IOLCP.BO's ROE of +0.11%. Regarding short-term risk, PGHL.NS is less volatile compared to IOLCP.BO. This indicates lower risk in terms of short-term price fluctuations for PGHL.NS.Check IOLCP.BO's competition here
Sequent Scientific Limited (NSE: SEQUENT.NS)
PGHL.NS vs SEQUENT.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while SEQUENT.NS trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to SEQUENT.NS's ROE of +0.08%. Regarding short-term risk, PGHL.NS is more volatile compared to SEQUENT.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check SEQUENT.NS's competition here
Sequent Scientific Limited (BSE: SEQUENT.BO)
PGHL.NS vs SEQUENT.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while SEQUENT.BO trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to SEQUENT.BO's ROE of +0.05%. Regarding short-term risk, PGHL.NS is more volatile compared to SEQUENT.BO. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check SEQUENT.BO's competition here
Morepen Laboratories Limited (BSE: MOREPENLAB.BO)
PGHL.NS vs MOREPENLAB.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, MOREPENLAB.BO has a market cap of 49.4B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while MOREPENLAB.BO trades at ₹90.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas MOREPENLAB.BO's P/E ratio is 52.11. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to MOREPENLAB.BO's ROE of +0.15%. Regarding short-term risk, PGHL.NS is more volatile compared to MOREPENLAB.BO. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check MOREPENLAB.BO's competition here
Morepen Laboratories Limited (NSE: MOREPENLAB.NS)
PGHL.NS vs MOREPENLAB.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, MOREPENLAB.NS has a market cap of 49.4B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while MOREPENLAB.NS trades at ₹90.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas MOREPENLAB.NS's P/E ratio is 26.20. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to MOREPENLAB.NS's ROE of +0.15%. Regarding short-term risk, PGHL.NS is more volatile compared to MOREPENLAB.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check MOREPENLAB.NS's competition here
Orchid Pharma Limited (NSE: ORCHPHARMA.NS)
PGHL.NS vs ORCHPHARMA.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, ORCHPHARMA.NS has a market cap of 48.7B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while ORCHPHARMA.NS trades at ₹960.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas ORCHPHARMA.NS's P/E ratio is 154.90. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to ORCHPHARMA.NS's ROE of +0.01%. Regarding short-term risk, PGHL.NS is more volatile compared to ORCHPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check ORCHPHARMA.NS's competition here
Orchid Pharma Limited (BSE: ORCHPHARMA.BO)
PGHL.NS vs ORCHPHARMA.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, ORCHPHARMA.BO has a market cap of 48.7B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while ORCHPHARMA.BO trades at ₹959.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas ORCHPHARMA.BO's P/E ratio is 561.10. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to ORCHPHARMA.BO's ROE of +0.01%. Regarding short-term risk, PGHL.NS is more volatile compared to ORCHPHARMA.BO. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check ORCHPHARMA.BO's competition here
Gujarat Themis Biosyn Limited (NSE: GUJTHEM.NS)
PGHL.NS vs GUJTHEM.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, GUJTHEM.NS has a market cap of 45.9B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while GUJTHEM.NS trades at ₹352.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas GUJTHEM.NS's P/E ratio is 82.02. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to GUJTHEM.NS's ROE of +0.04%. Regarding short-term risk, PGHL.NS is more volatile compared to GUJTHEM.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check GUJTHEM.NS's competition here
Gujarat Themis Biosyn Limited (BSE: GUJTHEM.BO)
PGHL.NS vs GUJTHEM.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, GUJTHEM.BO has a market cap of 45.8B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while GUJTHEM.BO trades at ₹351.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas GUJTHEM.BO's P/E ratio is 78.69. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to GUJTHEM.BO's ROE of +0.04%. Regarding short-term risk, PGHL.NS is more volatile compared to GUJTHEM.BO. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check GUJTHEM.BO's competition here
Aarti Drugs Limited (NSE: AARTIDRUGS.NS)
PGHL.NS vs AARTIDRUGS.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, AARTIDRUGS.NS has a market cap of 44.2B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while AARTIDRUGS.NS trades at ₹484.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas AARTIDRUGS.NS's P/E ratio is 22.80. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to AARTIDRUGS.NS's ROE of +0.15%. Regarding short-term risk, PGHL.NS is less volatile compared to AARTIDRUGS.NS. This indicates lower risk in terms of short-term price fluctuations for PGHL.NS.Check AARTIDRUGS.NS's competition here
Aarti Drugs Limited (BSE: AARTIDRUGS.BO)
PGHL.NS vs AARTIDRUGS.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, AARTIDRUGS.BO has a market cap of 44.2B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while AARTIDRUGS.BO trades at ₹484.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas AARTIDRUGS.BO's P/E ratio is 22.80. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to AARTIDRUGS.BO's ROE of +0.15%. Regarding short-term risk, PGHL.NS is less volatile compared to AARTIDRUGS.BO. This indicates lower risk in terms of short-term price fluctuations for PGHL.NS.Check AARTIDRUGS.BO's competition here
RPG Life Sciences Limited (NSE: RPGLIFE.NS)
PGHL.NS vs RPGLIFE.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, RPGLIFE.NS has a market cap of 42B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while RPGLIFE.NS trades at ₹2,540.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas RPGLIFE.NS's P/E ratio is 36.49. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to RPGLIFE.NS's ROE of +0.18%. Regarding short-term risk, PGHL.NS is more volatile compared to RPGLIFE.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check RPGLIFE.NS's competition here
RPG Life Sciences Limited (BSE: RPGLIFE.BO)
PGHL.NS vs RPGLIFE.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, RPGLIFE.BO has a market cap of 42B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while RPGLIFE.BO trades at ₹2,537.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas RPGLIFE.BO's P/E ratio is 36.43. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to RPGLIFE.BO's ROE of +0.18%. Regarding short-term risk, PGHL.NS is more volatile compared to RPGLIFE.BO. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check RPGLIFE.BO's competition here
Gufic Biosciences Limited (NSE: GUFICBIO.NS)
PGHL.NS vs GUFICBIO.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, GUFICBIO.NS has a market cap of 41.9B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while GUFICBIO.NS trades at ₹418.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas GUFICBIO.NS's P/E ratio is 57.10. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to GUFICBIO.NS's ROE of +0.11%. Regarding short-term risk, PGHL.NS is more volatile compared to GUFICBIO.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check GUFICBIO.NS's competition here
Gufic Biosciences Limited (BSE: GUFICBIO.BO)
PGHL.NS vs GUFICBIO.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, GUFICBIO.BO has a market cap of 41.9B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while GUFICBIO.BO trades at ₹418.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas GUFICBIO.BO's P/E ratio is 57.08. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to GUFICBIO.BO's ROE of +0.11%. Regarding short-term risk, PGHL.NS is more volatile compared to GUFICBIO.BO. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check GUFICBIO.BO's competition here
Evonile Pharma Limited (NSE: NOVARTIND.NS)
PGHL.NS vs NOVARTIND.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, NOVARTIND.NS has a market cap of 34.1B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while NOVARTIND.NS trades at ₹1,367.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas NOVARTIND.NS's P/E ratio is 35.91. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to NOVARTIND.NS's ROE of -0.01%. Regarding short-term risk, PGHL.NS is more volatile compared to NOVARTIND.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check NOVARTIND.NS's competition here
Evonile Pharma Limited (BSE: NOVARTIND.BO)
PGHL.NS vs NOVARTIND.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, NOVARTIND.BO has a market cap of 33.4B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while NOVARTIND.BO trades at ₹1,368.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas NOVARTIND.BO's P/E ratio is 35.16. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to NOVARTIND.BO's ROE of -0.01%. Regarding short-term risk, PGHL.NS is more volatile compared to NOVARTIND.BO. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check NOVARTIND.BO's competition here
Unichem Laboratories Limited (NSE: UNICHEMLAB.NS)
PGHL.NS vs UNICHEMLAB.NS Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, UNICHEMLAB.NS has a market cap of 33B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while UNICHEMLAB.NS trades at ₹468.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas UNICHEMLAB.NS's P/E ratio is 10.83. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to UNICHEMLAB.NS's ROE of +0.13%. Regarding short-term risk, PGHL.NS is more volatile compared to UNICHEMLAB.NS. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check UNICHEMLAB.NS's competition here
Unichem Laboratories Limited (BSE: UNICHEMLAB.BO)
PGHL.NS vs UNICHEMLAB.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, UNICHEMLAB.BO has a market cap of 33B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while UNICHEMLAB.BO trades at ₹469.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas UNICHEMLAB.BO's P/E ratio is 10.85. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to UNICHEMLAB.BO's ROE of +0.13%. Regarding short-term risk, PGHL.NS is more volatile compared to UNICHEMLAB.BO. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check UNICHEMLAB.BO's competition here
Solara Active Pharma Sciences Limited (BSE: SOLARA.BO)
PGHL.NS vs SOLARA.BO Comparison November 2026
Procter & Gamble Health Limited (NSE: PGHL.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PGHL.NS stands at 92.8B. In comparison, SOLARA.BO has a market cap of 30.4B. Regarding current trading prices, PGHL.NS is priced at ₹5,589.50 on the NSE, while SOLARA.BO trades at ₹628.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PGHL.NS currently has a P/E ratio of 26.01, whereas SOLARA.BO's P/E ratio is 81.74. In terms of profitability, PGHL.NS's ROE is +0.65%, compared to SOLARA.BO's ROE of +0.03%. Regarding short-term risk, PGHL.NS is more volatile compared to SOLARA.BO. This indicates higher risk in terms of short-term price fluctuations for PGHL.NS.Check SOLARA.BO's competition here